Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents.
作者信息
Tella Sri Harsha, Kommalapati Anuhya, Singhi Ryan K
机构信息
National Institutes of Health (NIH), Bethesda, USA.
Department of Medicine, University of South Carolina School of Medicine, Columbia, SC, USA.
出版信息
Transl Cancer Res. 2018 Feb;7(Suppl 1):S81-S84. doi: 10.21037/tcr.2018.01.07.
Abstract
摘要
相似文献
1
Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents.乳腺癌骨相关事件管理中的成本效益：一种骨改良剂低强度给药方案的策略。
Transl Cancer Res. 2018 Feb;7(Suppl 1):S81-S84. doi: 10.21037/tcr.2018.01.07.
2
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.唑来膦酸延长给药间隔与标准给药对骨转移患者骨骼事件的影响：一项随机临床试验
JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.
3
Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice.在骨髓瘤和骨转移中使用骨修饰剂：近期的给药间隔研究如何影响我们的实践。
J Oncol Pract. 2018 Aug;14(8):457-464. doi: 10.1200/JOP.18.00236.
4
Less Intense Dosing Schedule for a Bone-Modifying Agent.
JAMA Oncol. 2017 Jul 1;3(7):893-894. doi: 10.1001/jamaoncol.2016.6240.
5
Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study.骨修饰剂早期治疗对有骨转移的泌尿生殖系癌症患者预防骨骼相关事件的临床获益：一项多机构回顾性研究。
Int J Urol. 2019 Jun;26(6):630-637. doi: 10.1111/iju.13939. Epub 2019 Mar 18.
6
Assessment of the benefits of bone modifying agents in the management of advanced breast, prostate, and lung cancers.评估骨改良剂在晚期乳腺癌、前列腺癌和肺癌治疗中的益处。
Curr Opin Support Palliat Care. 2025 Jun 1;19(2):117-129. doi: 10.1097/SPC.0000000000000749. Epub 2025 Feb 14.
7
Management of bone loss due to endocrine therapy during cancer treatment.癌症治疗期间内分泌治疗所致骨质流失的管理。
Osteoporos Int. 2023 Apr;34(4):671-680. doi: 10.1007/s00198-023-06672-3. Epub 2023 Jan 19.
8
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.接受骨改良药物治疗的乳腺癌骨转移患者发生骨相关事件的危险因素。
Oncologist. 2016 Apr;21(4):508-13. doi: 10.1634/theoncologist.2015-0377. Epub 2016 Mar 14.
9
Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.常规临床实践中对乳腺癌骨转移患者使用的骨改良剂：治疗模式与结局
J Oncol Pharm Pract. 2020 Jun;26(4):906-911. doi: 10.1177/1078155219877929. Epub 2019 Oct 1.
10
Managing bone health with zoledronic acid: a review of randomized clinical study results.唑来膦酸治疗骨骼健康：随机临床研究结果综述。
Climacteric. 2011 Jun;14(3):321-32. doi: 10.3109/13697137.2010.529966. Epub 2010 Dec 23.
引用本文的文献
1
Construction of differentially expressed Her-2 related lncRNA-mRNA-miRNA ceRNA network in Her-2 positive breast cancer.人表皮生长因子受体2阳性乳腺癌中差异表达的人表皮生长因子受体2相关长链非编码RNA-信使核糖核酸-微小核糖核酸竞争性内源RNA网络的构建
Transl Cancer Res. 2020 Apr;9(4):2527-2533. doi: 10.21037/tcr.2020.03.34.
本文引用的文献
1
Evaluation and management of skeletal disease in cancer care.癌症护理中骨骼疾病的评估与管理。
Crit Rev Oncol Hematol. 2017 Dec;120:217-226. doi: 10.1016/j.critrevonc.2017.09.003. Epub 2017 Sep 8.
2
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).唑来膦酸每月一次、每三个月一次唑来膦酸以及地诺单抗每月一次用于乳腺癌伴骨转移女性患者的成本效益分析：CALGB 70604（联盟研究）
J Clin Oncol. 2017 Dec 10;35(35):3949-3955. doi: 10.1200/JCO.2017.73.7437. Epub 2017 Oct 12.
3
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.唑来膦酸每 12 周与 4 周给药在乳腺癌骨转移女性中的持续治疗效果：OPTIMIZE-2 随机临床试验。
JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316.
4
Less Intense Dosing Schedule for a Bone-Modifying Agent.
JAMA Oncol. 2017 Jul 1;3(7):893-894. doi: 10.1001/jamaoncol.2016.6240.
5
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.唑来膦酸延长给药间隔与标准给药对骨转移患者骨骼事件的影响：一项随机临床试验
JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.
6
Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.用于乳腺癌和前列腺癌骨转移的骨靶向药物使用情况：一项患者调查。
J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep.
7
De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.乳腺癌和前列腺癌患者中骨靶向药物的降阶梯给药——加拿大肿瘤学家的一项调查
J Bone Oncol. 2013 Apr 15;2(2):77-83. doi: 10.1016/j.jbo.2013.03.001. eCollection 2013 Jun.
8
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.一项评估降阶梯双膦酸盐疗法对骨转移相关事件低风险的转移性乳腺癌患者疗效的II期多中心试验。
Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.
9
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.在有发生骨相关事件风险的实体瘤骨转移成人患者中，地诺单抗与唑来膦酸相比的人均成本及潜在预算影响：奥地利、瑞典和瑞士的分析
Eur J Hosp Pharm. 2013 Aug;20(4):227-231. doi: 10.1136/ejhpharm-2012-000235. Epub 2013 Feb 21.
10
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.唑来膦酸每 12 周给药与每 4 周给药用于延长乳腺癌骨转移患者治疗时间的疗效和安全性（ZOOM）：一项开放标签、随机、非劣效性 3 期临床试验。
Lancet Oncol. 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16.
Zotero 插件